Oppenheimer launches Wall Street's first coverage of SpaceX with bullish outlook Ivar AI

Crypto Briefing

US launches strikes on Iran after Apache helicopter downed near Strait of Hormuz

Eldiario.es

EEUU anuncia una oleada de ataques contra Irán tras el derribo de un helicóptero Apache que patrullaba el estrecho de Ormuz

GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Donanimhaber.com

Yapay zekâ savaşında altyapı yarışı kızışıyor: Çin, 295 milyar dolarlık dev yatırım hazırlıyor

Crypto Briefing

Trump says Iran deal ‘very close,’ could impact troop withdrawal

New York Post

ChatGPT maker OpenAI files for IPO looking to capitalize on investor appetite for AI boom

El Financiero

Trump se ‘la cumple’ a Irán: Lanza ataques en represalia por derribo de helicóptero con 2 soldados de EU

Diariobitcoin.com

Acciones tokenizadas desbloquearán un mercado de USD $5 billones, afirma CEO de Securitize

Yahoo Entertainment

美國會遏阻伊朗無人機技術中東衝突升級油價飆漲

Macdailynews.com

Apple’s iPhone momentum shines bright: 19.7% YoY production surge positions it for market leadership amid industry headwinds

Mediaite

NEW: Trump Bombs Iran Second Night In a Row As Negotiations Falter

Www.abc.es

EE.UU. ataca Irán «en legítima defensa» por el «derribo» de un helicóptero en Ormuz

Ig.com.br

EUA iniciam ataques contra o Irã após queda de helicóptero

Crypto Briefing

Iran allegedly shoots down US Army Apache helicopter near Oman, triggering retaliatory strikes

Crypto Briefing

US fires 49 Tomahawk missiles at Iran in major escalation

Le HuffPost

Hegseth et Trump avaient prévenu, les États-Unis ont lancé de nouvelles frappes contre l’Iran

Crypto Briefing

Middle East oil output slashed by 11M bpd amid Strait of Hormuz blockade: EIA

CBS News

U.S. targets Iran's ammunition depots, more in new wave of strikes

PBS

U.S. launches new strikes in Iran after missiles target American bases

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire